TipRanks
Go Ultimate55% OFF

Implanet SA (ALIMP) Stock Price & Analysis

3 Followers

ALIMP Stock Chart & Stats

€0.14-€0.01(-8.11%)
At close: 5:30 PM GMT+1
€0.14€0.16€0.18Aug 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2
Day’s Range
EUR 0.13 - EUR 0.14
52-Week Range
EUR 0.13 - EUR 0.29
Previous Close
EUR 0.15
Volume
N/A
Average Volume (3M)
68.50K
Market Cap
EUR 21.29M
Enterprise Value
EUR 28.61M
Total Cash (Recent Filing)
EUR 1.01M
Total Debt (Recent Filing)
EUR 5.46M
Price to Earnings (P/E)
―
Beta
0.01
Next Earnings
Mar 09, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The strong multi-year revenue rebound indicates improving commercial traction for Implanet’s orthopedic and spine products. Continued top-line expansion can support greater operating scale, broader surgeon and hospital adoption, and a stronger foundation for eventual profitability.

Gross Margin Expansion

Meaningful gross-margin expansion improves the economic contribution of each product sale and creates more room to cover operating expenses. If maintained alongside revenue growth, this improvement could strengthen the company’s path toward reducing losses and funding future development.

Improving Operating Cash Flow

Although operating cash flow remains negative, the substantial year-over-year improvement suggests that cash absorption is moderating as the business expands. Sustaining this direction would reduce reliance on external funding and improve financial flexibility over the next several quarters.

Bears Say

Persistent Net Losses

Persistent operating and net losses show that revenue growth and higher gross margins have not yet translated into a sustainable earnings model. Continued losses can consume capital, restrict investment capacity, and delay the point at which growth becomes self-financing.

Negative Free Cash Flow

Ongoing negative free cash flow means Implanet is not yet generating enough cash internally to support its operations and investment needs. Until free cash flow turns sustainably positive, the company may remain dependent on financing and face less flexibility during periods of weaker performance.

High Leverage And Thin Equity

The very high debt load relative to a minimal equity base leaves limited protection against continued losses and weakens balance-sheet resilience. Prior negative equity also highlights material financial stress, while leverage can constrain capital allocation and increase dependence on funding support.

ALIMP FAQ

What was Implanet SA’s price range in the past 12 months?
Implanet SA lowest stock price was €0.13 and its highest was €0.29 in the past 12 months.
What is Implanet SA’s market cap?
Implanet SA’s market cap is €21.29M.
When is Implanet SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Implanet SA’s earnings last quarter?
Implanet SA released its earnings results on Sep 15, 2026. The company reported -€0.015 earnings per share for the quarter.
Is Implanet SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Implanet SA pay dividends?
Implanet SA does not currently pay dividends.
What is Implanet SA’s EPS estimate?
Implanet SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Implanet SA have?
Implanet SA has 143,818,970 shares outstanding.
What happened to Implanet SA’s price movement after its last earnings report?
Implanet SA reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went down -0.581%.
Which hedge fund is a major shareholder of Implanet SA?
Currently, no hedge funds are holding shares in FR:ALIMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology